IP Library Granted Patent US 9,949,991
Granted Patent B2
US 9,949,991 · App. 15/034,543 · Granted Apr 24, 2018

Methods of treating aquaporin-mediated conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,949,991
App. No.
15/034,543
Granted
Apr 24, 2018
Kind
B2
Abstract

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., glioblastoma and ovarian hyperstimulation syndrome. The invention provides, inter alia, methods of treating or controlling a disease condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.

Claims (29)

1. A method of treating or controlling a disease or condition selected from glioblastoma, ovarian hyperstimulation syndrome, pulmonary edema, fibromyalgia, and multiple sclerosis comprising administering to a patient in need thereof an effective amount of a compound of formula 1a:

wherein:

R 1 is selected from trifluoromethyl, chloro, fluoro, and bromo;

R 3 and R 5 are the same or different and selected from trifluoromethyl, chloro, fluoro, and bromo; and

R 2 and R 4 are both H; and

R 6 is selected from H and physiologically hydrolysable and acceptable acyl;

in free or pharmaceutically acceptable salt form.

2. The method of claim 1 , wherein:

R 1 is selected from chloro and bromo;

R 3 and R 5 are both trifluoromethyl; and

R 2 , R 4 , and R 6 are all H.

3. The method of claim 1 , wherein R 6 is a phosphono group, which may be substituted or unsubstituted.

4. The method of claim 1 , wherein the compound of formula 1a is selected from:

5. The method of claim 1 , wherein the compound of formula 1a is:

in free or pharmaceutically acceptable salt form.

6. The method of claim 1 , wherein the compound of formula 1a is:

in free form.

7. The method of claim 1 , wherein the compound of formula 1a is:

in free or pharmaceutically acceptable salt form.

8. The method of claim 6 , wherein the disease or condition is glioblastoma.

9. The method of claim 6 , wherein the disease or condition is ovarian hyperstimulation syndrome.

10. The method of claim 6 , wherein the disease or condition is pulmonary edema.

11. The method of claim 6 , wherein the disease or condition is fibromyalgia.

12. The method of claim 6 , wherein the disease or condition is multiple sclerosis.

13. The method of claim 7 , wherein the disease or condition is glioblastoma.

14. The method of claim 7 , wherein the disease or condition is ovarian hyperstimulation syndrome.

15. The method of claim 7 , wherein the disease or condition is pulmonary edema.

16. The method of claim 7 , wherein the disease or condition is fibromyalgia.

17. The method of claim 7 , wherein the disease or condition is multiple sclerosis.

Assignments (3)
ASSIGNEE CHANGE OF ADDRESS Recorded Oct 5, 2023
From: AEROMICS, INC.
To: AEROMICS, INC.
Reel/Frame 065155/0526 →
CERTIFICATE OF CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION Recorded Jul 3, 2016
From: AEROMICS, LLC
To: AEROMICS, INC.
Reel/Frame 039241/0887 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2016
From: PELLETIER, MARC F.; MCGUIRK, PAUL ROBERT; FARR, GEORGE WILLIAM; WILLIAMS, STEVEN
To: AEROMICS, LLC
Reel/Frame 038783/0732 →